SCHEMBL253204

SCHEMBL253204

Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2c(OC(C)N3CCOCC3)ccc3ccccc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.58
MAPK12 P53778 7/20 0.58
MAPK13 O15264 6/20 0.58
MAPK11 Q15759 6/20 0.58
TNF P01375 4/20 0.58
MAPK9 P45984 3/20 0.58
DDR2 Q16832 2/20 0.58
HCK P08631 2/20 0.58
ABL1 P00519 2/20 0.58
RAF1 P04049 2/20 0.58
LYN P07948 2/20 0.58
SRC P12931 2/20 0.58
CIT O14578 1/20 0.58
MUSK O15146 1/20 0.58
MAP3K7 O43318 1/20 0.58
RIPK2 O43353 1/20 0.58
STK10 O94804 1/20 0.58
MAP4K4 O95819 1/20 0.58
CHEK2 O96017 1/20 0.58
EGFR P00533 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7964926 0.85 MAPK14 (0.78) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL296487 0.80 MAPK14 (0.76) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL20876925 0.80 MAPK14 (0.76) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL29593381 0.80 MAPK14 (0.76) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL7963067 0.78 MAPK14 (0.80) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL29593331 0.78 MAPK14 (0.77) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL295153 0.78 MAPK14 (0.77) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL29594073 0.75 MAPK14 (0.77) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL297064 0.75 MAPK14 (0.77) MAPK14MAPK12MAPK13MAPK11TNF
SCHEMBL30335874 0.75 MAPK14 (0.65) MAPK14MAPK12MAPK13MAPK11TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170204192-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS, INC. 2017-07-20 US disclosed
US-20150191545-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS, INC. 2015-07-09 US disclosed
EP-2860260-A1 Human serum albumin linkers and conjugates thereof Merrimack Pharmaceuticals, Inc. (US) 2015-04-15 EP disclosed
US-8927694-B2 Human serum albumin linkers and conjugates thereof MERRIMACK PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
EP-2288715-B1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS INC (US) 2014-09-24 EP disclosed
US-20120003221-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS, INC. (US) 2012-01-05 US disclosed
US-20110059076-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS, INC. 2011-03-10 US disclosed
WO-2010059315-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF MERRIMACK PHARMACEUTICALS, INC. (US) 2010-05-27 WO disclosed
WO-2009124056-A2 ALPHA-FETOPROTEIN FOR TREATING DISEASE MERRIMACK PHARMACEUTICALS, INC. (US) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120003221-A1 HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF ALB, HDGF, VCAM1 MAPK14 2506/4885MAPK12 2818/4885MAPK13 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.